Download PDF
Semin Reprod Med 2004; 22(1): 51-60
DOI: 10.1055/s-2004-823027
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Aromatase and Leiomyoma of the Uterus

Makio Shozu1 , Kouich Murakami1 , Masaki Inoue1
  • 1Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Kanazawa, Japan
Further Information

Publication History

Publication Date:
13 April 2004 (online)

    Permissions and Reprints

In leiomyoma of the uterus, both aromatase and 17β-hydroxysteroid dehydrogenase (17β-HSD) type I are overexpressed compared with myometrium. This suggests that leiomyoma cells convert circulating androstenedione into estrone (via aromatase), then into the active form of estrogen, estradiol (via 17β-HSD type I). In vitro experiments and several clinical findings support the notion that in situ estrogen plays a role in leiomyoma growth under hypoestrogenemic conditions, such as natural menopause and therapy with gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists abolish estrogen production both in situ in leiomyoma and in the ovary, leading to quick and profound regression of the leiomyoma. Aromatase inhibitors also inhibit estrogen synthesis in both leiomyoma and the ovary and may be used therapeutically. Certain doses of competitive aromatase inhibitors would completely inhibit estrogen production in leiomyoma, whereas ovarian production of estrogen would continue at reduced levels. This may lead to advantageous therapeutic conditions in which leiomyoma regresses without adverse symptoms related to estrogen depletion because levels of ovarian estrogen would be insufficient to support leiomyoma growth but sufficient to prevent symptoms associated with deficiency. This article discusses the potential uses of aromatase inhibitors.

KEYWORDS

Leiomyoma of the uterus - aromatase - estrogen - aromatase inhibitor

REFERENCES

  • 1 Folkerd E J, Newton C J, Davidson K, Anderson M C, James V H. Aromatase activity in uterine leiomyomata.  J Steroid Biochem. 1984;  20 1195-1200
    CrossrefPubMedGoogle Scholar
  • 2 Takamori K, Yamamoto T, Okada H. Estrogen biosynthesis in human uterine myoma tissue: the distribution of androstenedione aromatase activity in uterine myoma tissue.  Nippon Sanka Fujinka Gakkai Zasshi. 1984;  36 1861-1866
    PubMedGoogle Scholar
  • 3 Yamamoto T, Takamori K, Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus.  Horm Metab Res. 1984;  16 678-679
    PubMedGoogle Scholar
  • 4 Bulun S E, Simpson E R, Word R A. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture.  J Clin Endocrinol Metab. 1994;  78 736-743
    CrossrefPubMedGoogle Scholar
  • 5 Sumitani H, Shozu M, Segawa T et al.. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism.  Endocrinology. 2000;  141 3852-3861
    CrossrefPubMedGoogle Scholar
  • 6 Gabb R G, Stone G M. Uptake and metabolism of tritiated oestradiol and oestrone by human endometrial and myometrial tissue in vitro.  J Endocrinol. 1974;  62 109-123
    PubMedGoogle Scholar
  • 7 Pollow K, Sinnecker G, Boquoi E, Pollow B. In vitro conversion of estradiol-17beta into estrone in normal human myometrium and leiomyoma.  J Clin Chem Clin Biochem. 1978;  16 493-502
    PubMedGoogle Scholar
  • 8 Eiletz J, Genz T, Pollow K, Schmidt-Gollwitzer M. Sex steroid levels in serum, myometrium, and fibromyomata in correlation with cytoplasmic receptors and 17 beta-HSD activity in different age-groups and phases of the menstrual cycle.  Arch Gynecol. 1980;  229 13-28
    PubMedGoogle Scholar
  • 9 Newton C J, James V H. 17 beta-hydroxysteroid dehydrogenase activity in leiomyoma and myometrium and its relationship to concentrations of oestrone, oestradiol and progesterone throughout the menstrual cycle.  J Steroid Biochem. 1985;  22 487-493
    CrossrefPubMedGoogle Scholar
  • 10 Yamamoto T, Urabe M, Naitoh K, Kitawaki J, Honjo H, Okada H. Estrone sulfatase activity in human uterine leiomyoma.  Gynecol Oncol. 1990;  37 315-318
    CrossrefPubMedGoogle Scholar
  • 11 Van de Ven J, Donker T H, Blankenstein M A, Thijssen J H. Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium.  Fertil Steril. 2002;  77 1227-1232
    CrossrefPubMedGoogle Scholar
  • 12 Englund K, Blanck A, Gustavsson I et al.. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment.  J Clin Endocrinol Metab. 1998;  83 4092-4096
    CrossrefPubMedGoogle Scholar
  • 13 Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy.  Hum Reprod. 1999;  14 2844-2850
    CrossrefPubMedGoogle Scholar
  • 14 Regidor P A, Schmidt M, Callies R, Kato K, Schindler A E. Estrogen and progesterone receptor content of GnRH analogue pretreated and untreated uterine leiomyomata.  Eur J Obstet Gynecol Reprod Biol. 1995;  63 69-73
    CrossrefPubMedGoogle Scholar
  • 15 Pasqualini J R, Cornier E, Grenier J, Vella C, Schatz B, Netter A. Effect of decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium.  Fertil Steril. 1990;  53 1012-1017
    PubMedGoogle Scholar
  • 16 Otubu J A, Buttram V C, Besch N F, Besch P K. Unconjugated steroids in leiomyomas and tumor-bearing myometrium.  Am J Obstet Gynecol. 1982;  143 130-133
    PubMedGoogle Scholar
  • 17 Shozu M, Sumitani H, Segawa T, Yang H J, Murakami K, Inoue M. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate.  J Clin Endocrinol Metab. 2001;  86 5405-5411
    CrossrefPubMedGoogle Scholar
  • 18 Shozu M, Sumitani H, Segawa T et al.. Over-expression of aromatase P-450 in leiomyoma tissues is driven through the promoter I.4 of aromatase P-450.  J Clin Endocrinol Metab. 2002;  87 2540-2548
    CrossrefPubMedGoogle Scholar
  • 19 Casey M L, MacDonald P C, Mitchell M D, Snyder J M. Maintenance and characterization of human myometrial smooth muscle cells in monolayer culture.  In Vitro. 1984;  20 396-403
    PubMedGoogle Scholar
  • 20 Palmberg L, Thyberg J. Uterine smooth muscle cells in primary culture: alterations in fine structure, cytoskeletal organization and growth characteristics.  Cell Tissue Res. 1986;  246 253-262
    PubMedGoogle Scholar
  • 21 Dumin J, Wilcox B D, Otterness I, Melendez J A, Huang C, Jeffrey J J. Serotonin-mediated production of interstitial collagenase by uterine smooth muscle cells requires interleukin-1alpha, but not interleukin-1beta.  J Biol Chem. 1998;  273 25488-25494
    CrossrefPubMedGoogle Scholar
  • 22 Wilcox B D, Dumin J A, Jeffrey J J. Serotonin regulation of interleukin-1 messenger RNA in rat uterine smooth muscle cells: relationship to the production of interstitial collagenase.  J Biol Chem. 1994;  269 29658-29664
    PubMedGoogle Scholar
  • 23 Zhao Y, Mendelson C R, Simpson E R. Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes.  Mol Endocrinol. 1995;  9 340-349
    CrossrefPubMedGoogle Scholar
  • 24 Kurose T, Hando T, Shiota A. Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma.  Nippon Sanka Fujinka Gakkai Zasshi. 1995;  47 35-41
    PubMedGoogle Scholar
  • 25 Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women.  Fertil Steril. 2001;  76 38-43
    CrossrefPubMedGoogle Scholar
  • 26 Adamson G D. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists.  Am J Obstet Gynecol. 1992;  166 746-751
    PubMedGoogle Scholar
  • 27 Demopoulos R I, Mesia A F. Effects of leuprolide acetate on treatment of leiomyomata: clues to mechanisms of action.  Adv Anat Pathol. 1998;  5 129-136
    PubMedGoogle Scholar
  • 28 Friedman A J, Lobel S M, Rein M S, Barbieri R L. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.  Am J Obstet Gynecol. 1990;  163 1114-1119
    PubMedGoogle Scholar
  • 29 Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.  J Obstet Gynaecol Res. 2000;  26 325-331
    PubMedGoogle Scholar
  • 30 Friedman A J, Daly M, Juneau-Norcross M, Gleason R, Rein M S, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin “add-back” for 2 years.  Hum Reprod. 1994;  9 1618-1625
    CrossrefPubMedGoogle Scholar
  • 31 Andersen J. Growth factors and cytokines in uterine leiomyomas.  Semin Reprod Endocrinol. 1996;  14 269-282
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Shozu M, Sumitani H, Murakami K, Segawa T, Yang H-J, Inoue M. Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase.  J Steroid Biochem Mol Biol. 2001;  79 61-65
    CrossrefPubMedGoogle Scholar
  • 33 Chegini N, Verala J, Luo X, Xu J, Williams R S. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy.  J Soc Gynecol Investig. 2003;  10 161-171
    CrossrefPubMedGoogle Scholar
  • 34 Iveson T J, Smith I E, Ahern J, Smithers D A, Trunet P F, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.  Cancer Res. 1993;  53 266-270
    PubMedGoogle Scholar
  • 35 Lee M J, Kazer R R. Massive ascites after leuprolide acetate administration for the treatment of leiomyomata uteri.  Fertil Steril. 1992;  58 416-418
    PubMedGoogle Scholar
  • 36 Harding S G, Pesce A, McMillan L. Symptomatic ascites complicating GnRH analogue use for myoma shrinkage.  Br J Obstet Gynaecol. 1993;  100 1054-1056
    PubMedGoogle Scholar
  • 37 Moudgal N R, Shetty G, Selvaraj N, Bhatnagar A S. Use of a specific aromatase inhibitor for determining whether there is a role for oestrogen in follicle/oocyte maturation, ovulation and preimplantation embryo development.  J Reprod Fertil Suppl. 1996;  50 69-81
    PubMedGoogle Scholar
  • 38 Palter S F, Tavares A B, Hourvitz A, Veldhuis J D, Adashi E Y. Are estrogens of import to primate/human ovarian folliculogenesis?.  Endocr Rev. 2001;  22 389-424
    CrossrefPubMedGoogle Scholar
  • 39 Mitwally M F, Casper R F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.  Fertil Steril. 2001;  75 305-309
    CrossrefPubMedGoogle Scholar
  • 40 Selvaraj N, Bhatnagar A S, Moudgal N R. Is there a role for estrogen in follicular maturation in the primate?.  Endocrine. 1995;  3 245-249
    PubMedGoogle Scholar
  • 41 Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency.  J Clin Endocrinol Metab. 1991;  72 560-566
    CrossrefPubMedGoogle Scholar
  • 42 Conte F A, Grumbach M M, Ito Y, Fisher C R, Simpson E R. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).  J Clin Endocrinol Metab. 1994;  78 1287-1292
    CrossrefPubMedGoogle Scholar
  • 43 Morishima A, Grumbach M M, Simpson E R, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.  J Clin Endocrinol Metab. 1995;  80 3689-3698
    CrossrefPubMedGoogle Scholar
  • 44 Shozu M, Zhao Y, Simpson E R. Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene.  Endocrinology. 1997;  138 5125-5135
    CrossrefPubMedGoogle Scholar
  • 45 Shozu M, Simpson E R. Aromatase expression of human osteoblast-like cells.  Mol Cell Endocrinol. 1998;  139 117-129
    CrossrefPubMedGoogle Scholar
  • 46 Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of symptomatic uterine leiomyoma with a non-steroidal aromatase inhibitor in a perimenopausal woman.  Fertil Steril. 2003;  79 628-631
    CrossrefPubMedGoogle Scholar

Makio ShozuM.D. 

Department of Obstetrics and Gynecology, Kanazawa University School of Medicine

13-1 Takara-machi, Kanazawa 920-0934, Japan